In COVID-19 clinical update #89, Dr. Griffin reviews upcoming meeting on FDA emergency use authorization for molnupiravir, 25% of US cases in children, reinfection associates with presence of antibodies, national surveillance for acute flaccid myelitis in the US, and monoclonal antibody treatment of infection in vaccinated, high-risk individuals.
TWiV explains that a recent report suggesting that the SARS-CoV-2 spike protein inhibits V(D)J recombination in vitro would not impact immunity after infection or vaccination, and describes the isolation of remdesivir resistant mutants in cells in culture, and the emergence of amino acid changes in the spike protein identical to those in variants of concern, in the absence of immune selection.
A TWiV duo reviews how SARS-CoV-2 attacks the olfactory mucosa but spares the olfactory bulb, vaccination with BNT162b2 induces virus-specific stem cell memory T cells, and development of an oral protease inhibitor for the treatment of COVID-19.
In COVID-19 clinical update #88, Dr. Griffin covers vaccine protection among US veterans, absence of long COVID in vaccinated who are infected, single dose of REGEN-COV monoclonal antibody cocktail provides long term protection, and Pfizer protease inhibitor Paxlovid is 89% effective in preventing hospitalization or death.
Greg Zuckerman joins TWiV to discuss his book that explores the race to produce COVID-19 vaccines, with insights into the companies, scientists, and executives involved and the rivalries, ambitions, ego, and a desire to save the world.
In COVID-19 clinical update #87, Dr. Griffin reviews PCR cycle threshold and RNA copy number, rapid antigen tests, hospitalization rate after infection or vaccination, allergies and vaccination, community transmission and viral RNA load, early treatment with sotrovimab, meta-analysis of tocilizumab treatment, antibiotic overuse, and guidelines on the use of anticoagulation for thromboprophylaxis.
In this special live-streamed episode of TWiV, Dr. Daniel Griffin fields questions on SARS-CoV-2 and COVID-19 from listeners.
TWiV explores the properties of the spike glycoproteins of an influenza B virus discovered in the Wuhan spiny eel, and protection against SARS-CoV-2 infection one year after mRNA-1273 vaccination of nonhuman primates.
Rich reviews the history of smallpox and the discovery of variola viral genomes in ancient DNA from human remains throughout Northern Europe, which pushes back the earliest date of smallpox virus infection to ~600–1050 CE, overlapping the Viking Age.
A TWiV trio reveal the isolation of novel paramyxoviruses from rodents and bats in Arizona, and isolation of naive B cells from seronegative donors that produce germline encoded antibodies which engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses from bats.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Brianne Barker, Ph.D.
Rich Condit, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Angela Mingarelli, DVM
Jolene Ramsey, Ph.D.
Kathy Spindler, Ph.D.